Bovie Medical (BVX) Tops Q4 EPS by 2c, Beats on Revenues; Offers FY18 Revenues Outlook Above Consensus

Bovie Medical (NYSE: BVX) reported Q4 EPS of ($0.03), $0.02 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $9.85 million.

Fourth Quarter 2017 Financial Summary:

• Total Q4 revenue of approximately $11.3 million, up 20% year-over-year.
  • Advanced Energy revenue of $3.1 million, up 219% year-over-year, driven by strong J-Plasma® sales.
  • Core revenue of approximately $7.7 million, up 2% year-over-year.
  • OEM revenue of approximately $0.6 million, down 42% year-over-year.

2018 Outlook:

• The Company expects total revenue in the range of $41.0 million to $42.5 million, representing growth of 5% to 9% year-over-year. The Company expects total revenue growth to be driven by Advanced Energy sales growth in the range of approximately 40% to 45% year-over-year.
• The Company expects adjusted EBITDA in a range of $1.0 million to $1.5 million.

GUIDANCE:

Bovie Medical sees FY2018 revenue of $41-42.5 million, versus the consensus of $40.58 million.

For earnings history and earnings-related data on Bovie Medical (BVX) click here.

You May Also Be Interested In

• Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
• AT&T (T) beats earnings estimates in Q1 but revenue falls short, shares climb
• Fortive (FTV) Tops Q1 EPS by 4c ; Offers Guidance